Free shipping on all orders over $ 500

Abemaciclib (LY2835219)

Cat. No. M10347

All AbMole products are for research use only, cannot be used for human consumption.

Abemaciclib (LY2835219) Structure
Synonym:

LY2835219 free base

Size Price Availability Quantity
5mg USD 50 In stock
25mg USD 80 In stock
50mg USD 110 In stock
Free Delivery on orders over USD 500 Bulk Inquiry?

Quality Control & Documentation
Biological Activity

Abemaciclib (LY2835219) is a best-in-class, selective and effective dual inhibitor of CDK4 and CDK6, which inhibits CDK4/CDK6 activity with IC50 of 2 nM and 10 nM respectively. LY2835219 is an orally effective cyclin-dependent kinase (CDK) inhibitor that targets CDK4 (Cyclin D1) and CDK6 (cyclin D3) cell cycle pathways and has potential antitumor activity. LY2835219 specifically inhibits CDK4 and 6, thereby inhibiting the phosphorylation of retinoblastoma (Rb) protein in the early G1 phase. Abemaciclib (LY2835219) inhibits Rb phosphorylation and prevents CDK-mediated G1-S phase transition, resulting in cell cycle stagnation in G1 phase, inhibiting DNA synthesis, and inhibiting cancer cell growth.


Chemical Information
Molecular Weight 506.59
Formula C27H32F2N8
CAS Number 1231929-97-7
Solubility (25°C) DMSO 3 mg/mL (ultrasonic and warming)
Storage 2-8°C, protect from light, sealed
References

[1] İbrahim Ethem Cakcak, et al. Turk J Med Sci. An experimental study: the effect of S. boulardii on abemaciclibinduced diarrhea

[2] Bo Mi Ku, et al. Oncotarget. The CDK4/6 inhibitor LY2835219 has potent activity in combination with mTOR inhibitor in head and neck squamous cell carcinoma

[3] Vipin Yadav, et al. Mol Cancer Ther. The CDK4/6 inhibitor LY2835219 overcomes vemurafenib resistance resulting from MAPK reactivation and cyclin D1 upregulation

[4] Lawrence M Gelbert, et al. Invest New Drugs. Preclinical characterization of the CDK4/6 inhibitor LY2835219: in-vivo cell cycle-dependent/independent anti-tumor activities alone/in combination with gemcitabine

Related CDK Products
AT7519

AT7519 is a novel small molecule multi-cyclin-dependent (CDK) kinase inhibitor.

Flavopiridol

Flavopiridol (Alvocidib) is a competitive broad-spectrum CDK inhibitor with IC50 of 30,170,100 nM against CDK1, CDK2 and CDK4, respectively.

R547

R547 is a potent and selective ATP-competitive CDK inhibitor, with Ki values of 2 nM, 3 nM and 1 nM for CDK1/cyclin B, CDK2/cyclin E and CDK4/cyclin D1, respectively.

JNJ-7706621

JNJ-7706621 is a dual cell cycle inhibitor with activity against cyclin-dependent kinases (CDK1, 2, 3, 6) with an IC50 of 3-175 nM and Aurora kinases (A and B) with an IC50 of 11-15 nM respectively.

PD 0332991 HCL

PD-0332991 HCl is a highly selective inhibitor of CDK4/6 with IC50 of 11 nM/16 nM in cell-free assays, respectively. It shows no activity against CDK1/2/5, EGFR, FGFR, PDGFR, InsR, etc.

  Catalog
Abmole Inhibitor Catalog




Keywords: Abemaciclib (LY2835219), LY2835219 free base supplier, CDK, inhibitors, activators

All AbMole products are for research use only, cannot be used for human consumption or veterinary use. We do not provide products or services to individuals. Please comply with the intended use and do not use AbMole products for any other purpose.



Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2026 AbMole BioScience. All Rights Reserved.